Via: BMO Capital Markets
Bottom Line:
Continuing the BMO Healthcare Hidden Gems series, we hosted a call with Outset Medical (private), an emerging medical technology company set to disrupt the treatment of kidney failure with its Tablo device. Tablo is a “simple, flexible and untethered “ solution to shift the treatment paradigm for dialysis patients, creating a true consumer experience by utilizing digital health tools and reducing labor and infrastructure costs.
Key Points
Outset Medical is positioned to transform the $80-90 billion dialysis market (including $34 billion spent by Medicare each year, or 7% of the Medicare budget) by introducing a new on-demand and self-care treatment platform called Tablo for both acute (ICU) and chronic (in-center) dialysis treatment. The device’s key pillars include: 1) consumer design; 2) infrastructure free dialysis; and 3) wireless data transmission.
Read More: https://bmo.bluematrix.com/docs/shorthtml/1c451604-e151-4ab0-9655-e5d438882a00.html
RSS Feed
